J Acquir Immune Defic Syndr. 2026 Feb 6. doi: 10.1097/QAI.0000000000003845. Online ahead of print.
ABSTRACT
BACKGROUND: F/TAF was shown to be non-inferior to F/TDF as pre-exposure prophylaxis (PrEP) in men, but approval was not extended to cisgender women. We report the results of PrEPVacc, in which a predominantly female population was randomly allocated to receive daily oral F/TDF or F/TAF for ∼6 months within a HIV-1 prophylactic vaccine trial.
SETTING: Five study sites in three African countries (Uganda, Tanzania, South Africa).
METHODS: The two regimens were compared by the averted infections ratio (AIR) – the proportion of infections averted by F/TAF relative to F/TDF. The counterfactual HIV incidence, an essential component of this metric, was derived from a preceding registration cohort. Dried blood spots (DBS) were collected at regular timepoints for later assessment of tenofovir diphosphate levels in selected sub-populations.
RESULTS: 1380 participants (697 F/TDF, 683 F/TAF) were included in the primary analysis (total follow-up 709.2 person-years); 87% were cisgender women. Three HIV infections (0.86/100 person-years) occurred in the F/TAF group versus two in the F/TDF group (0.56/100 person-years). The counterfactual HIV incidence was estimated to be 2.59/100 person-years (90% CI 1.86-3.52), giving an AIR of 0.85 (90% CI 0.31-1.66). Based on the week 8 DBS sample , only an estimated 14% of participants were classified as taking 2-3 tablets per week and 9% ≥4 tablets per week.
CONCLUSIONS: Despite similar HIV incidence rates, the non-inferiority of F/TAF was not demonstrated, probably due to low statistical power primarily driven by low adherence. However, there is compelling evidence from multiple studies supporting the efficacy of F/TAF as PrEP regardless of sex.
PMID:41650395 | DOI:10.1097/QAI.0000000000003845
